Factors Affecting Medication Adherence to Topical Acne Medications: a Single-center, Prospective Study Evaluating the Adherence and Patient Satisfaction to Single and Multiple Topical Acne Medications
| Registry | NCT05582434 |
|---|---|
| Status | Active not recruiting |
| Phase | Early Phase 1 |
| Study type | Interventional; randomized, parallel, masking: none, treatment |
| Enrollment | 72 (Actual) |
| Sponsor | Wake Forest University Health Sciences (Other); collaborators: Bausch Health Americas, Inc. |
| Conditions | Acne |
| Interventions | clindamycin phosphate 1.2%/adapalene 0.15%/BPO 3.1% gel, adapalene 0.3%/BPO 2.5% gel and compounded clindamycin phosphate 1.2% gel, Compounded BPO 2.5% gel, adapalene 0.1% gel, and compounded clindamycin phosphate 1.2% gel (Drug) |
| Dates | start 2024-02-15, primary completion 2025-06-19, completion 2026-11-01 (estimated), first posted 2022-10-17, last updated 2025-12-24 |
| Locations | 1 site in United States |
Related Papers Related Patents Related Grants Related Experts
All trials for Acne All trials of clindamycin phosphate 1.2%/adapalene 0.15%/BPO 3.1% gel All trials of adapalene 0.3%/BPO 2.5% gel and compounded clindamycin phosphate 1.2% gel
Acne is a chronic condition that typically requires the use of multiple medications.1 Medication adherence is especially challenging for patients with chronic diseases and often decreases over time, especially for those using topical medications.1 Nonadherence can result in multiple negative effects including treatment failure, increased healthcare costs, and decreased quality of life. Primary nonadherence refers to problems acquiring and starting treatment. Challenges to this form of nonadherence include a lack of knowledge, misunderstanding of usage, poor communication with provider, increased cost, and fear of side effects.2 Secondary nonadherence refers to when the patient does not use the medication as prescribed. Hurdles to secondary nonadherence include delayed results, increased complexity of treatment plan, adverse effects, busy lifestyle, and inconvenience.2
| Arm | Type | Interventions | Description |
|---|---|---|---|
| One single fixed-combination product | Experimental | Drug: clindamycin phosphate 1.2%/adapalene 0.15%/BPO 3.1% gel | Participants instructed to apply clindamycin phosphate 1.2%/adapalene 0.15%/BPO 3.1% gel once daily |
| Two products | Experimental | Drug: adapalene 0.3%/BPO 2.5% gel and compounded clindamycin phosphate 1.2% gel | Participants instructed to apply 0.3%/BPO 2.5% gel and compounded clindamycin phosphate 1.2% gel once daily |
| Three products | Experimental | Drug: Compounded BPO 2.5% gel, adapalene 0.1% gel, and compounded clindamycin phosphate 1.2% gel | Participants instructed to apply BPO 2.5% gel, adapalene 0.1% gel, and compounded clindamycin phosphate 1.2% gel once daily |
Sex: All, ages: 18 Years to 85 Years
Inclusion Criteria: 1. Adult patients ≥18 years of age 2. Patients with a current diagnosis of acne 3. Patients who live in the US, 4. Patients have sufficient command of the English language Exclusion Criteria: 1. Patients less than the age of 18 2. Patients without a current diagnosis of acne 3. Patients who do not live in the US 4. Patients without a sufficient command of the English language
| Facility | City | Country | Status |
|---|---|---|---|
| Wake Forest University Health Sciences | Winston-Salem, North Carolina | United States |